To stay competitive, Europe must adopt a regulatory framework that supports and incentivizes continuous innovation in the off-patent and value-added medicines sector. At Winmedica, we see Greece’s and Europe’s potential as a strong production hub for off-patent pharmaceuticals. Our own €65 million investment plan of establishing a new oncology R&D and production facility in Tripoli, Arkadia, is a testament to our commitment to advancing local European manufacturing and innovation.
🌟 The EU must do more to support affordable innovation by creating a framework for value added and repurposed medicines, which can bring new treatment opportunities to patients.